AstraZeneca
AstraZeneca’s drug scores positive results against chemo in breast cancer
February 17, 2017Medical Communications, Research and Development AstraZeneca
AstraZeneca announced that its drug, Lynpara (olaparib), had positive results for a recent Phase 3 trial when tested against standard …
NICE turns down AZ’s chronic obstructive pulmonary disease drug
February 13, 2017Sales and Marketing AstraZeneca, Daxas, NICE, chronic obstructive pulmonary disease
AstraZeneca’s Daxas (roflumilast) has been knocked back in draft guidance by the National Institute for Health and Care Excellence (NICE), …
AZ to rework ongoing immuno-oncology trials to “enhance options”
January 17, 2017Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, non-small cell lung cancer
Due to the “strong efficacy” shown by its durvalumab as a treatment for non-small cell lung cancer (NSCLC), AstraZeneca has …
MSD looks to jump the gun with combination immunotherapy application
January 11, 2017Research and Development, Sales and Marketing AstraZeneca, BMS, MSD, Roche, immunotherapy, keytruda
MSD, known as Merck in North America, has launched a bold move by filing Keytruda, and being accepted, for Priority …
AstraZeneca acquires biotech’s unique antithrombotic drug
January 5, 2017Medical Communications, Sales and Marketing APT, AstraZeneca, acquisition
AstraZeneca has announced that it has entered into a research collaboration, option and asset purchase agreement with APT Therapeutics, a …
Pfizer announces acquisition of small-molecule business from AZ for $550 million
December 23, 2016Medical Communications AstraZeneca, Pfizer
Pfizer has announced that they have acquired AstraZeneca’s small molecule anti-infectives business for an upfront fee of $550 million. Pfizer …
AZ oncology head leaves to become Innate Pharma chairman
December 21, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Innate Pharma
French firm Innate Pharma has announced that the current-AstraZeneca head of oncology is joining the company as chairman of the …
AstraZeneca opens £120 million UK manufacturing facility
December 20, 2016Manufacturing and Production AstraZeneca, Macclesfield
AstraZeneca has officially opened a new manufacturing facility for cancer medicines based in Macclesfield, UK. It becomes the second largest …
AZ oncology head leaves to become Innate Pharma chairman
December 19, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Innate Pharma
French firm Innate Pharma has announced that the current-AstraZeneca head of oncology is joining the company as chairman of the …
AZ secures rights from Ionis for first-ever antisense KRAS cancer drug in $165m deal
December 19, 2016Research and Development, Sales and Marketing AstraZeneca, Ionis, KRAS
AstraZeneca has paid a $28 million milestone payment in its partnership with Ionis Pharmaceuticals over the licensing rights to anticancer …
Five major pharma firms break ABPI code of conduct, according to watchdog
December 15, 2016Medical Communications, Sales and Marketing ABPI, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Grunenthal, Janssen
Eli Lilly, Boehgringer Ingelheim, AstraZeneca UK, Grunenthal and Janssen-Cilag have been “named and shamed” by the Prescription Medicines Code of …
AZ to terminate 700 US jobs
December 9, 2016Manufacturing and Production, Medical Communications AstraZeneca, job cuts
AstraZeneca has revealed that it plans to cut 700 positions across the US by 10 February 2017, including 120 positions …
AZ lung cancer drug cuts disease progression by 70%
December 7, 2016Research and Development AstraZeneca, Tagrisso
AstraZeneca is touting its cancer drug Tagrisso (osimertinib) as a potential new standard of care for epidermal growth factor receptor …
AstraZeneca seals $1 billion deal with Bicycle Therapeutics
December 2, 2016Medical Communications, Sales and Marketing AstraZeneca, Bicycle Therapeutics
Bicycle Therapeutics, Cambridge-based British biotech firm, has announced that it has signed a deal that could potentially be worth over …
GSK reaches endgame of race to develop anaemia drug
November 25, 2016Research and Development, Sales and Marketing AstraZeneca, Daprodustat, GSK, GlaxoSmithKline, anaemia
GlaxoSmithKline has announced that they will begin Phase 3 development of their anaemia drug, daprodustat. The drug is an oral …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
